Investors & Media

Corporate Profile

DBV Technologies is developing Viaskin®, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, we are dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV Technologies is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY.

Investor Relations


Sara Blum Sherman
Senior Director
Investor Relations & Strategy
+1 212-271-0740
sara.sherman@dbv-technologies.com

Media Relations


Joe Becker
VP, Global Corporate Communications
+1 646-650-3912
joseph.becker@dbv-technologies.com

Subscribe
to get the latest
DBV press releases

Press Releases

DocumentYearTerms

03/20/2020 - 9:15 pm

DBV Technologies Announces Filing of 2019 Universal Registration Document and 2019 Annual Report on Form 20-F

Download PDF (122 KB)

03/17/2020 - 9:00 pm

Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 29, 2020 and March 4, 2020

Download PDF (78 KB)

03/16/2020 - 9:30 pm

DBV Technologies Provides Update on Viaskin Peanut BLA for Children Ages 4-11 Years

Download PDF (153 KB)